Clinical trials: Drug Drug Interaction (DDI)
Healthy
Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim
This is a Phase 1, single-centre, fixed-sequence, open label, drug-drug interaction study in 2 groups of healthy subjects. Group A: to evaluate the effects of itraconazole, a strong inhibitor of cytochrome P450 3A (CYP3A), upon…
- Trial name
- NCT04171739
- Testing
- Itraconazole oral solution, Rifampicin Oral Capsule, Olorofim
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Healthy
Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)
Fixed sequence, 2-period crossover study to compare the pharmacokinetic profiles of Palbociclib in absence and presence of prior administration of proton pump inhibitor Rabeprazole.
- Trial name
- NCT01918176
- Testing
- Palbociclib alone, Palbociclib + Rabeprazole
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Bacterial Infections
A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants
A phase 1, randomized, double blind, placebo controlled drug-drug interaction, pharmacokinetics and safety study of cefiderocol in combination with xeruborbactam in healthy adult participants
- Trial name
- NCT06547554
- Testing
- Xeruborbactam, Cefiderocol, Xeruborbactam/Cefiderocol
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Drug Drug Interaction (DDI)
Study on the Drug Interaction Between Buagafuran and Voriconazole
This study is a non-randomized, open label trial aimed at evaluating the drug interaction between Buagafuran capsules and voriconazole tablets in Chinese adult healthy participants.The research period is 7 days in total.
- Trial name
- NCT07457203
- Testing
- Buagafuran, Voriconazole
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Beijing Union Pharmaceutical Factory Ltd
Healthy Participants
Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers
This study will evaluate the safety and tolerability, pharmacokinetic, and pharmacodynamic profile, and drug-drug interaction (DDI) of casdatifan in healthy participants.
- Trial name
- ARC-14 (NCT05117554)
- Testing
- casdatifan, Midazolam
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Arcus Biosciences, Inc.
AML (Acute Myeloid Leukemia), Glioma
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
- Conditions
- AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies
- Trial name
- NCT07486713
- Testing
- Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Rigel Pharmaceuticals
Drug-Drug Interaction (DDI), Healthy Subjects
A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects
ASP3652 is being investigated as a novel treatment for chronic pelvic pain. This is a two-part study to investigate the drug-drug potential of ASP3652.
- Trial name
- NCT01797198
- Testing
- ASP3652, Gemfibrozil, Repaglinide
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants
The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on how fast different formulations of midazolam gets into the blood stream and how long it takes the body to remove it when administered in…
- Trial name
- NCT06180967
- Testing
- Midazolam Syrup, Midazolam Solution, Pirtobrutinib
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
DDI Study With Multiple-dose LX4211 and Single Dose Digoxin
This study will be conducted as a single-center, open-label, 2-period, single-sequence, drug-drug interaction study to assess the effects of multiple dose LX4211 (400 mg administered as 2 × 200-mg tablets qd × 12 days) on the PK…
- Trial name
- NCT02300350
- Testing
- Treatment A digoxin, Treatment B LX4211, Treatment C Digoxin + 400 mg LX4211 administered concomitantly
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Healthy
A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers
A single 125 mg oral dose of the investigational compound PD-0332991 will be administered alone and after steady-state dosing of tamoxifen to determine if coadministration of tamoxifen alters the plasma pharmacokinetics of…
- Trial name
- NCT01821066
- Testing
- PD-0332991 alone, Tamoxifen 60 mg, Tamoxifen 20 mg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Malaria
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole
The study will assess the effect of multiple doses of itraconazole, a strong CYP3A4/5 inhibitor, on the PK of ganaplacide and lumefantrine in healthy participants.
- Trial name
- NCT05084651
- Testing
- Ganaplacide, Lumefantrine, Itraconazole
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Clinical Trial, Phase I
Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan
This is a study in postmenopausal women to investigate the Drug-drug interaction (DDI) between itraconazole(ITZ) and orally administered vilaprisan; absolute bioavailability using intravenous microtracer dose of [14C]vilaprisan.
- Trial name
- NCT02456129
- Testing
- Vilaprisan (BAY1002670), [14C] Vilaprisan, Itraconazole(ITZ)
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.
- Trial name
- NCT07785934
- Testing
- UBT251, Metformin hydrochloride, Warfarin Sodium
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Multiple Sclerosis
GSK239512 DDI Study
The study will determine the effect of 400 mg once daily of ketoconazole at steady state on the pharmacokinetics of a single oral dose of GSK239512 in young healthy volunteers.
- Trial name
- NCT01802931
- Testing
- GSK239512, ketoconazole
- Where
- Australia
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pharmacokinetics of ASP8477, Pharmacodynamics of ASP8477
A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males
This is a 4-part study. Part I assesses the safety and tolerability of single ascending doses of ASP8477 or a placebo under fasted conditions in postmenopausal subjects.
- Trial name
- NCT02220777
- Testing
- ASP8477, omeprazole
- Where
- 2 sites in Belgium, France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
The main purpose of this study is to evaluate the effect of Pirtobrutinib (LOXO-305) on multiple oral doses of digoxin (P-gp substrate) when administered as single and multiple doses by collecting the blood samples and conducting…
- Trial name
- NCT06194214
- Testing
- Pirtobrutinib, Digoxin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Subjects
A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers
This study is to determine the effect of single and multiple oral doses of mifepristone on the pharmacokinetics of a single oral dose of fluvastatin administered to healthy volunteers.
- Trial name
- NCT00752843
- Testing
- mifepristone + fluvastatin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Drug Drug Interaction (DDI)
A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects
This clinical trial is a phase 1, open-label, fixed-sequence, drug-drug interaction study to investigate the effect of single and multiple oral doses of SB17170 on the pharmacokinetics of SB_MDZ in healthy adult subjects.
- Trial name
- NCT06846684
- Testing
- SB17170, SB_MDZ
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- SPARK Biopharma
Malaria
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir
The purpose of this study is to assess the effect of multiple doses of ganaplacide and lumefantrine combination on the substrates of cytochrome P450 (CYP) 3A4 (midazolam), CYP2C8 (repaglinide), CYP2D6 (dextromethorphan), organic…
- Trial name
- NCT05236530
- Testing
- Midazolam, Repaglinide, Dextromethorphan
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Subjects, Infection, Human Immunodeficiency Virus
DDI Study of Etravirine and GSK1265744
The primary objective of this study is to compare steady-state plasma PK, safety and tolerability of GSK1265744 with and without etravirine
- Trial name
- NCT00920296
- Testing
- GSK1265744
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline